News
GlobalData on MSN1d
Supernus makes depression drug play with $795m Sage buyoutAfter Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill ...
Neurology specialist Supernus Pharmaceuticals will snap up Sage Therapeutics, which was once valued at more than $9 billion, ...
Stifel analysts said the deal “feels like an unremarkable outcome for a company that was once one of the hottest stories in ...
In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per ...
The terms include an upfront payment of $8.50 per share for Sage, giving Supernus rights to its FDA-approved post-partum ...
Supernus Pharmaceuticals Inc. is buying Sage Therapeutics Inc. for about $795 million. The deal brings Supernus, already firmly in the CNS market, the only U.S. FDA-approved oral treatment for ...
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Sage Therapeutics, Inc. (NASDAQ: SAGE) to Supernus Pharmaceuticals, Inc. is fair to Sage shareholders. Under the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback